This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Press Archive


ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics

Garching / Munich, Germany, October 24, 2023 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today reported on its participation at the 3rd International Centers for Precision Oncology (ICPO) Forum for Theranostics in Precision Oncology which took place in Garching near Munich, Germany, from October 12-13, 2023. The company also announced support for the ICPO’s newly established Academy for Theranostics, which was unveiled as part of the event.

The hosting organization, ICPO is an independent German foundation working on progressing access to Radiomolecular Precision Oncology (RPO) diagnostics and treatments for cancer patients globally. Over 200 international participants were in attendance from fields including oncology, nuclear medicine, and patient advocacy. The event took place in the Science Congress Center Munich, a location neighboring ITM’s headquarters and production facilities for n.c.a. Lutetium-177.

ITM participated in the Forum to share key insights for production and supply measures as a leading expert in Radiopharmaceutical Therapy (RPT). Company representatives also presented the esteemed Maurits W. Geerlings Next Generation Award and contributed to the launch of the ICPO Academy for Theranostics.

Dr. Michael Siegl, Product Manager at ITM, presented the company’s strategy for meeting future demand through capacity expansion during a “Production and Delivery: Radiomolecular Theranostics at the Cross-roads” speaker session. Dr. Siegl reviewed how ITM applies its expertise as the world’s largest manufacturer of the highly coveted n.c.a. Lutetium-177 to ensure it is prepared to address future demand for Actinium-225 as alpha-emitting isotopes become increasingly important.

As part of the conference, Richard Henkelmann, Managing Director of ITM’s subsidiary ITM Medical Isotopes, had the honor of presenting the 2nd Maurits W. Geerlings Next Generation Award for outstanding research and contributions in Actinium-225 radiopharmaceuticals to Dr. Sanjana Ballal, Research Associate-Medical Physicist at the All India Institute of Medical Sciences (AIIMS) in New Delhi, India, and Dr. Mariza Vorster, Head of the Clinical Department and Associate Professor at the Kwa-Zulu Natal and Inkosi Albert Luthuli Hospital in South Africa. Dr. Geerlings, co-founder and the first Chairman of ITM, was a pioneer in the field of theranostics and launched ITM together with co-founders, Mr. Henkelmann and Mr. Oliver Buck to develop innovative radiopharmaceuticals for the diagnosis and treatment of cancer.

ITM also announced its support for the ICPO Academy for Theranostics, which was unveiled at the event. With over 30 contributing experts, this training platform offers approximately 50 hours of video-based e-learning education to physicians, medical physicists, radiochemists and nurses interested in applying radiotheranostics to their clinical practice. The program, comprised of three workstreams, culminates with participants passing all training modules and being awarded an international RPO certificate. As part of a two months pilot phase involving over 700 participants from 300 hospitals, the first 340 certificates were granted to participants who had successfully completed the first level of the course, thereby earning an international certificate in the fundamental theoretical training of RPT in precision oncology.

As part of a public private partnership with the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ GmbH), ITM has been significantly supporting and thus enabling the development of the pilot phase. The company has furthermore pledged to bolster the program with 100-150 stipends per year to provide participants with full access to the online educational program in order to obtain the final certificate. Additionally, ITM will assist the ICPO in expanding the availability of the training program to various geographies including India as a next step in its continued development of the program.

“We highly value the opportunity to participate in the ICPO forum with other experts in the field and are honored to support the launch and growth of the ICPO Academy for Theranostics. The number of promising new diagnostics and therapeutics being developed in nuclear medicine is on the rise. Educational programs like the Academy will ensure that highly trained experts are able to apply these methods to provide patients around the world with improved care and outcomes,” commented Steffen Schuster, CEO of ITM.

About ITM Isotope Technologies Munich SE

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

ITM Contact
Corporate Communications
Svenja Gärtner / Gerrit Siegers
Phone: +49 89 329 8986 1502

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009